Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
76.72
+0.82 (+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
2 Top Dividend Stocks to Buy Hand Over Fist
March 17, 2024
Every company faces headwinds eventually. The top ones know how to bounce back.
Via
The Motley Fool
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
March 16, 2024
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...
Via
Talk Markets
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
March 15, 2024
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today
March 11, 2024
Via
Benzinga
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
March 11, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Balancing Dividends and Fundamentals: The Case of NASDAQ:GILD.
March 05, 2024
Exploring GILEAD SCIENCES INC (NASDAQ:GILD)'s dividend characteristics.
Via
Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
February 23, 2024
Via
Benzinga
3 Dividend Stocks to Buy Hand Over Fist in March
March 10, 2024
Income investors might want to load up on these great dividend stocks.
Via
The Motley Fool
The AI Race Gets Litigious
March 09, 2024
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...
Via
Benzinga
Exposures
Product Safety
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
March 06, 2024
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed.
Via
Benzinga
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
March 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
March 04, 2024
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.
Via
InvestorPlace
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
March 04, 2024
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
February 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
February 27, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
February 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...
Via
Talk Markets
3 Dividend Stocks That Are No-Brainer Buys Right Now
February 24, 2024
These stocks check off multiple boxes for investors.
Via
The Motley Fool
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
February 24, 2024
This biotech stock could be poised for a nice rebound if analysts are right.
Via
The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
Gilead Sciences to Present at Upcoming Investor Conferences
February 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Stock Alert: 3 Market Giants on the Brink of Monumental Rallies
February 20, 2024
These are the stocks to buy to unlock the secrets of market giants in various industries for monumental growth and returns.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.